Robert Rifkin

7PUBLICATIONS
18CO-AUTHORS
Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Regenerative medicine (incl. stem cells)Medical mycologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 09, 2023
In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma.

Robert M Rifkin, Caitlin L Costello, Ruemu E Birhiray

|Sep 19, 2023
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management.

Robert M Rifkin, Saulius K Girnius, Stephen J Noga

|Feb 13, 2023
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma.

Barry Paul, Michaela Liedtke, Jack Khouri

|Aug 06, 2019
Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry.

Howard R Terebelo, Rafat Abonour, Cristina J Gasparetto

Pageof 2